Quote from Maverick74:
No gamma risk. I constructed this trade to minimize the vol implosion on the long premium. I did this by buying the guts. Very little vol premium on those. This gives me a lot of upside on either a big up move or big down move. By selling the march vol, I am pretty much protected if the stock doesn't move as the march vol will come in probably 50 pts. Basically, anything over 30 and I am styling. Also if the FDA rejects the drug, I am sitting pretty on a sharp move down to 15 or so. If the stock goes above 40, well, it will turn out very nicely. Personally this stock could open anywhere from 12 to 50. It's anybody's guess. I'm also leaning long deltas.
But this is a huge drug and would literally double the size of their company and make them a possible buyout candidate. The sleep aid business is a 3 billion dollar a year industry that will be over 5 billion in a couple of years. Right now, Ambien owns that space. But this drug supposedly does not allow the user to build up immunity to it over time and also avoids the common morning after hangover associated with sleeping pills.
But the situation is not as black and white as getting approved or not. The key will be in the wording. SEPR is looking for the FDA to verify the studies that show that it indeed does do the things it says it does. Also, shareholders of the stock are looking for some guidance as to how aggressively the drug can be marketed and sold. People want to see this drug on the shelves by this summer. That is very aggressive. So approval can take many forms. If the drug gets a full approval and they can get this thing out fast, well, $50 a share is not unreasonable.
Also, I am not long the Aprils. Aprils are way too pricey.